Agenda – Orexo Capital Markets Day, Stockholm, Sweden, Dec. 6
Uppsala, Sweden – November 28, 2018 –Orexo AB (publ.), the specialty pharmaceutical company, invites as earlier communicated investors, analysts and media to its Capital Markets Day in Stockholm, Sweden, on December 6, at Armémuseet, Riddargatan 13.
The agenda of the day is presented below. To register for the event please use this link (https://financialhearings.com/event/11536/register/live_event)
| Time pm CET | Topic | Presenter |
| 1:00 – 1:05 | Welcoming remarks | CharlotteStjerngren, Moderator |
Part 1 – Strategic initiatives to leverage strong platform |
||
| 1:05 – 1:35 | Taking Orexo to a new height | Martin Nicklasson, Chairman of the Board of Directors |
| Building from excellence and strengths | Nikolaj Sørensen, CEO and President | |
| Q&A session | ||
Part 2 – Well-positioned in a market expected to retain strong growth |
||
| 1:35 – 2:30 | US addiction market is likely to maintain strong growth | External Speaker,Dan Hawkins, Founder & Managing Director Clarion Healthcare |
| Orexo US is ready to capitalize on the growing market | Robert A. DeLuca, President Orexo US Inc. & Joseph DeFeo, EVP and Chief Financial Officer | |
| Q&A session | ||
| 2:30 – 2:50 | Break | |
Part 3 – Embrace all faces of opioid addiction |
||
| 2:50 – 3:50 | Opioid addiction is a chronic brain disease | External Speaker, Fred Nyberg, PhD, Professor, Division of Biological Research on Drug Dependence, Uppsala University |
| Panel session - Creating a product portfolio to treat opioid dependence | Johannes Doll, EVP and Head of Corporate Development, Michael Sumner, Chief Medical Officer & Robert Rönn, Head of Pharmaceutical Development and IP |
|
| Q&A session | ||
| 3:50 – 4:00 | Break | |
Part 4 – The US opioid crisis is one of largest national health crises ever |
||
| 4:00 – 4:50 | Perspectives on the opioid crisis and how to combat it | Keynote Speaker, Chris Christie, 55th Governor of New Jersey and former Chairman of the US President’s Commission on Combating Drug Addiction and the Opioid Crisis |
| Q&A session | ||
| 4:50-5:00 | Concluding remarks | Nikolaj Sørensen & Charlotte Stjerngren |
Changes can be made to the agenda until the day when the Capital Markets Day will take place
For further information, please contact:
| Orexo AB (publ.) | ||
| Lena Wange, IR and Communications Manager | ||
| Tel: +46 (0)18 780 88 00 | ||
| E-mail: ir@orexo.com Consilium Strategic Communications Mary-Jane Elliott / Jonathan Birt / Olivia Manser / Carina Jurs Tel: +44 (0)20 3709 5700 E-mail: orexo@consilium-comms.com |
||
About Orexo
Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The products are commercialized by Orexo in the US or via selected partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo sells the product Zubsolv®. Total net sales for 2017 amounted to SEK 643.7 million and the number of employees at year-end was 90. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala, Sweden.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.
Tags: